Myrjam De Keyser1, Maya De Belder2, Jonas De Belder1, Veva De Groot1,3. 1. Department of Medicine, University of Antwerp, Antwerp, Belgium. 2. Department of Experimental Psychology, Ghent University, Ghent, Belgium. 3. Department of Ophthalmology, University Hospital Antwerp, Edegem, Belgium.
Abstract
PURPOSE: We examined selective laser trabeculoplasty (SLT) as a replacement therapy for medically controlled open-angle glaucoma (OAG) or ocular hypertensive patients. METHODS: A prospective randomized interventional clinical trial on 143 glaucoma patients. Patients were randomized to either receiving SLT or to the control group that continued on pressure lowering medication. Data were recorded 1 hr, 1 week, 1, 3, 6, 12 and 18 months after SLT. Primary outcome was number of medications at 12 and 18 months while maintaining a predetermined target intraocular pressure (IOP). RESULTS:Selective laser trabeculoplasty (SLT) reduced number of medications from a mean of 1.5 at baseline, to 0.35 after 12 months and 0.29 after 18 months. Meanwhile, SLT achieved more than 20% IOP lowering in 95% of eyes and more than 30% IOP lowering in 86% of eyes after 18 months. Seventy-seven per cent of our eyes no longer needed any medication after SLT at 18 months. CONCLUSION:Selective laser trabeculoplasty (SLT) enabled a reduction in number of medications while maintaining good IOP control. Selective laser trabeculoplasty (SLT) was able to completely replace medical therapy in 77% of eyes after 18 months. Selective laser trabeculoplasty (SLT) as replacement therapy may reduce local and systemic side-effects and prevent adherence issues.
RCT Entities:
PURPOSE: We examined selective laser trabeculoplasty (SLT) as a replacement therapy for medically controlled open-angle glaucoma (OAG) or ocular hypertensivepatients. METHODS: A prospective randomized interventional clinical trial on 143 glaucomapatients. Patients were randomized to either receiving SLT or to the control group that continued on pressure lowering medication. Data were recorded 1 hr, 1 week, 1, 3, 6, 12 and 18 months after SLT. Primary outcome was number of medications at 12 and 18 months while maintaining a predetermined target intraocular pressure (IOP). RESULTS: Selective laser trabeculoplasty (SLT) reduced number of medications from a mean of 1.5 at baseline, to 0.35 after 12 months and 0.29 after 18 months. Meanwhile, SLT achieved more than 20% IOP lowering in 95% of eyes and more than 30% IOP lowering in 86% of eyes after 18 months. Seventy-seven per cent of our eyes no longer needed any medication after SLT at 18 months. CONCLUSION: Selective laser trabeculoplasty (SLT) enabled a reduction in number of medications while maintaining good IOP control. Selective laser trabeculoplasty (SLT) was able to completely replace medical therapy in 77% of eyes after 18 months. Selective laser trabeculoplasty (SLT) as replacement therapy may reduce local and systemic side-effects and prevent adherence issues.
Authors: Christiane R Rolim-de-Moura; Augusto Paranhos; Mohamed Loutfi; David Burton; Richard Wormald; Jennifer R Evans Journal: Cochrane Database Syst Rev Date: 2022-08-09
Authors: Ricardo Y Abe; Heloísa A Maestrini; Guilherme B Guedes; Marcelo M Nascimento; Camila I Iguma; Hérika Danielle de Miranda Santos; Muna Georges Nasr; Ricarte P Lucena-Junior; Tiago S Prata Journal: Sci Rep Date: 2022-02-04 Impact factor: 4.379
Authors: Nathan Radcliffe; Gus Gazzard; Thomas Samuelson; Peng Khaw; Xinghuai Sun; Tin Aung; Dennis Lam; Kuldev Singh; L Jay Katz; Michael Aronov; Zachary Sacks; Yoram Solberg; Richard Lindstrom; Michael Belkin Journal: J Glaucoma Date: 2022-06-15 Impact factor: 2.290